Drug intelligence / Profile preview

NNC0502-2021

Development stage: Unknown
Lead developer: Novo Nordisk
Administration: Subcutaneous

Overview

NNC0502-2021 is an investigational drug developed by Novo Nordisk, identified only by its code name in public records. As of October 2025, there are no publicly available details regarding its chemical structure, mechanism of action, modality, route of administration, or therapeutic indication. The compound has appeared in internal and external Novo Nordisk clinical trial records, but no trial records with explicit results or study phase information are found for NNC0502-2021 in public clinical trial registries or major pharmaceutical databases. Its status beyond being a proprietary trial compound under development by Novo Nordisk is unconfirmed.

Other names: NNC0502-2021NNC-0502-2021NNC 0502-2021

Beyond the preview

Go deeper on NNC0502-2021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0502-2021.

Explore the full profile